Abbott VP McCoy sells 585 common shares

Abbott Laboratories vice president and controller John A. McCoy Jr. reported multiple transactions in Abbott common shares.

Rhea-AI Filing Summary

Abbott Laboratories vice president and controller John A. McCoy Jr. reported multiple transactions in Abbott common shares. On March 2, 2026, he completed an open-market sale of 585 shares at $115.58 per share. On February 27, 2026, he disposed of 1,142 shares at $116.26 per share to cover tax obligations by delivering shares rather than cash. After these transactions, he held 24,628 common shares directly. A separate indirect holding of 58 shares was reported in a Profit Sharing Trust, with the balance noted as of February 27, 2026.

Insider Trade Summary

Net Seller: 585 shares

Net Sell 3 txns

Insider MCCOY JOHN A. JR.

Role VICE PRESIDENT AND CONTROLLER

Sold 585 shs ($68K)

Type	Security	Shares	Price	Value
Sale	Common shares without par value	585	$115.58	$68K
Exercise Price or Tax Liability	Common shares without par value	1,142	$116.26	$133K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 24,628 shares (Direct); Common shares without par value — 58 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. F1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ABBOTT LABORATORIES (ABT) report for John A. McCoy Jr.?

ABBOTT LABORATORIES reported that John A. McCoy Jr. sold 585 common shares in an open-market transaction and disposed of 1,142 shares to cover tax obligations. These activities were disclosed as part of a Form 4 insider transaction report for Abbott common shares.

How many ABBOTT LABORATORIES (ABT) shares did John A. McCoy Jr. sell on March 2, 2026?

On March 2, 2026, John A. McCoy Jr. sold 585 ABBOTT LABORATORIES common shares in an open-market transaction at a reported price of $115.58 per share. This sale reduced his directly held Abbott share balance reported in the filing.

What was the purpose of the 1,142 ABBOTT LABORATORIES (ABT) shares disposed of on February 27, 2026?

The 1,142 ABBOTT LABORATORIES shares disposed of on February 27, 2026 were used to satisfy tax obligations by delivering shares instead of cash. The transaction was identified with code F, indicating a tax-withholding disposition rather than an ordinary open-market sale.

How many ABBOTT LABORATORIES (ABT) shares does John A. McCoy Jr. hold after these Form 4 transactions?

After the reported transactions, John A. McCoy Jr. directly holds 24,628 ABBOTT LABORATORIES common shares. The filing also reports an additional 58 Abbott shares held indirectly in a Profit Sharing Trust, with that trust balance stated as of February 27, 2026.

What indirect ABBOTT LABORATORIES (ABT) holdings are reported for John A. McCoy Jr.?

The Form 4 reports an indirect holding of 58 ABBOTT LABORATORIES common shares for John A. McCoy Jr. in a Profit Sharing Trust. A footnote specifies this figure represents the balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:55 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCOY JOHN A. JR.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VICE PRESIDENT AND CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/27/2026		F		1,142	D	$116.26	25,213	D
Common shares without par value	03/02/2026		S		585	D	$115.58	24,628	D
Common shares without par value								58(1)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

	/s/ John A. McCoy, Jr. by Jessica H. Paik, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.